Aresus Pharma Acquires Rights to Veregen® Drug and Stocks of the Active Ingredient
April, 2019 - Duesseldorf, Germany
A team led by Fabian G. Gaffron, Partner at Heuking Kühn Lüer Wojtek, advised pharmaceutical company Aresus Pharma GmbH on the acquisition of the rights to the dermatological drug Veregen® and the stocks of the active pharmaceutical ingredient from Medigene AG. As part of the sale, all relevant contracts with distribution partners and external service providers will be transferred from Medigene to Aresus Pharma. The U.S. rights are held by U.S. company Fougera Pharmaceuticals Inc. Aresus Pharma intends to continue investing in Veregen® in the future.
Aresus Pharma GmbH is a young company focusing on the global commercialization and clinical research of Veregen®. Company founders Sven Schimansky-Wabra and Dr. Francisco Harrison are managing a portfolio of companies for the development and marketing of additional semi-solid products and a specialist company for regulatory matters.
Counsel to Aresus Pharma GmbH
Heuking Kühn Lüer Wojtek:
Fabian G. Gaffron (M&A/Tax/Lead),
Dr. Jörg Schewe (Corporate/Commercial),
Christoph Prochnau, LL.B. (Corporate/Commercial),
Sarah Slavik-Schulz (Tax/Commercial),
Dr. Kai Erhardt (Finance),
Dr. Volker Voth (Employment), all Hamburg
